SCHEMBL17488028

SCHEMBL17488028

Cc1cc(Nc2ccc3[nH]c(NCc4ccc(Oc5ncc(Cl)cn5)cc4)nc3c2)n[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 7/20 0.41
NTRK1 P04629 3/20 0.41
PAK4 O96013 3/20 0.41
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GSK3B P49841 3/20 0.38
PIK3C3 Q8NEB9 1/20 0.38
RET P07949 4/20 0.38
AURKA O14965 2/20 0.38
SRC P12931 1/20 0.38
DAPK3 O43293 1/20 0.38
JAK2 O60674 1/20 0.38
ABL1 P00519 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
CSF1R P07333 1/20 0.38
IGF1R P08069 1/20 0.38
PDGFRB P09619 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17488029 0.93 RAB9A (0.43) PLK4NTRK1PAK4MEN1HTT
SCHEMBL17488061 0.90 NTRK1 (0.48) PLK4NTRK1PAK4GSK3BRET
SCHEMBL17488330 0.84 PLK4 (0.39) PLK4NTRK1PAK4MEN1HTT
SCHEMBL17488143 0.83 RAB9A (0.40) HTTAURKAKDRAURKBTP53
SCHEMBL17488243 0.80 PLK4 (0.42) PLK4NTRK1PAK4KMT2AHSD17B10
SCHEMBL17488153 0.80 RAB9A (0.43) HTTAURKAKDRAURKBTP53
SCHEMBL17487846 0.79 LMNA (0.41) PLK4NTRK1PAK4GSK3BPIK3C3
SCHEMBL18965903 0.77 SMN1; SMN2 (0.39) HTTGSK3BKDRGSK3ACLK4
SCHEMBL17488145 0.77 RAB9A (0.41) HTTKDRTP53RAB9ASMN1; SMN2
SCHEMBL17487532 0.75 PLK4 (0.40) PLK4NTRK1PAK4GSK3BPIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 US disclosed
WO-2016016421-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS ALOX5, ALOX15, ALOX12 PLK4 3683/4885NTRK1 1236/4885PAK4 4387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.